S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

$1.71
+0.09 (+5.56 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.67
Now: $1.71
$1.75
50-Day Range N/A
52-Week Range
$1.20
Now: $1.71
$3.51
Volume375,400 shs
Average Volume579,624 shs
Market Capitalization$115.00 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Read More
OncoCyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.98 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$115.00 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.71
+0.09 (+5.56 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for OncoCyte
.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for OncoCyte
.

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.03. The biotechnology company earned $0.14 million during the quarter, compared to the consensus estimate of $0.04 million.
View OncoCyte's earnings history
.

What price target have analysts set for OCX?

5 brokers have issued 1 year price targets for OncoCyte's stock. Their forecasts range from $2.00 to $7.50. On average, they anticipate OncoCyte's share price to reach $4.70 in the next twelve months. This suggests a possible upside of 174.9% from the stock's current price.
View analysts' price targets for OncoCyte
.

Has OncoCyte been receiving favorable news coverage?

News articles about OCX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about OncoCyte
.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,870,000 shares, an increase of 52.0% from the June 15th total of 1,230,000 shares. Based on an average trading volume of 702,600 shares, the short-interest ratio is currently 2.7 days.
View OncoCyte's Short Interest
.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.43%), EAM Investors LLC (0.36%), P.A.W. Capital Corp (0.30%), Private Wealth Partners LLC (0.22%), Bank of New York Mellon Corp (0.17%) and New York State Common Retirement Fund (0.06%). Company insiders that own OncoCyte stock include Albert P Parker, Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter.
View institutional ownership trends for OncoCyte
.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp.
View insider buying and selling activity for OncoCyte
.

Which major investors are buying OncoCyte stock?

OCX stock was acquired by a variety of institutional investors in the last quarter, including EAM Investors LLC, Private Wealth Partners LLC, Bank of New York Mellon Corp, New York State Common Retirement Fund, Phoenix Holdings Ltd., Virtu Financial LLC, American International Group Inc., and Goldman Sachs Group Inc.. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter.
View insider buying and selling activity for OncoCyte
.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.71.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $115.00 million. OncoCyte employs 12 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.